ARKG ARK Genomic Revolution ETF
NASDAQ Health Care GR EUR

NAV as of 24-May-2022

30.9100

4 Week: 28.08 - 37.21

52 Week: 28.08 - 93.10

Latest Closing Price

30.91

Premium / Discount

0.06

Expense Ratio

0.75%

Investment Objective

The investment seeks long-term growth of capital. The fund is an actively-managed exchange-traded fund ("ETF") that will invest under normal circumstances primarily (at least 80% of its assets) in domestic and foreign equity securities of companies across multiple sectors, including healthcare, information technology, materials, energy and consumer discretionary, that are relevant to the fund's investment theme of the genomics revolution ("Genomics Revolution Companies"). It is non-diversified.

Main Fund Characteristics

Fund Manager:
Ark ETF Trust
Asset Under Management:
2,576,129,648
Launch Date:
29/10/2014
Asset Class:
Equity
Replication Method:
Not Applicable
Number of Holdings:
49
Trading Currency:
USD
Style:
Small Growth
Region/Sector/Strategy:
N.A / Healthcare / N.A
Exchange:
CBOEBZX

Performance

Period Performance Returns(%) Volatility(%) Risk Adjusted Performance
YTD-49.534.05-12.24
1 Day-5.070.000.00
1 Week-5.708.46-0.67
1 Month-19.0824.18-0.79
3 Months-32.7934.01-0.96
6 Months-52.5643.90-1.20
1 Year-60.8948.41-1.26
2 Years-37.6366.18-0.57
3 Years1.2479.650.02
5 Years47.2690.490.52
10 Years0.000.000.00

Price History

-

Annual Performance Return

2012201320142015201620172018201920202021
Price (%) 0.00000.00000.0000-1.5144-18.356645.40530.589443.7493180.5062-33.8913
Nav (%) 0.00000.00000.00000.00000.00000.00000.00000.00000.00000.0000
Rank 0.00000.00000.0000100.000087.00004.000050.00005.00001.0000100.0000

Dividend Frequency

Lastest Dividend

Ex Date Payment Date Dividend Payout per unit
28/12/202130/12/20210.3824
28/12/202030/12/20200.7901

Portfolio Data

Total Number of Holdings: 49

Number of Bond Holdings: 0

Number of Equity Holdings: 47

Total Market Value: 2,576,129,648

Portfolio Composition

Top 10 Holdings

% Portfolio Weight Shares Owned Shares Changed Market Value
1Ionis Pharmaceuticals Inc9.39106,129,323-23,232241,924,379

Country Exposure

Regional Exposure

America

Greater Europe

Greater Asia

Market Classification

Market Capitalization

Size% of portfolio
Giant1.55
Large5.43
Medium20.67
Small35.66
Micro36.53

Equity Style Box Breakdown

000Large
000Mid
000Small
ValueBlendGrowth

Value Measures

Price/Prospective Earnings*

17.4600

Price/Book*

1.0666

Price/Sales*

1.2610

Price/Cash Flow*

12.4225

Dividend Yield*

0.0553

Growth Measures

Long-Term Earnings

24.6060

Historical Earnings

34.0356

Sales Growth

18.0378

Cash-Flow Growth

55.1403

Book-Value Growth

69.5494

*Forward-looking based on historical data.

Equity Sector

Number of Bond Holdings

0

Bond Statitics

DetailValue
Average Effective Duration0
Average Effective Maturity (Years)*0
Average Credit Quality0
Average Weighted Coupon*0
Average Weighted Price*0

Bond Style Box Breakdown

000HighQuality
000Med
000Low
LtdModExt
Interest-Rate Sensitivity

Credit Quality

Type% Bonds
N.A

Bond Sector

Type
% Bonds

Bond Maturity

% Bonds
N.A

Data Source: Morningstar

© 2019 Morningstar. All Rights Reserved. The information, data, analyses and opinions (“Information”) contained herein:

(1) include the proprietary information of Morningstar and Morningstar’s third party licensors;
(2) may not be copied or redistributed except as specifically authorised;
(3) do not constitute investment advice;
(4) are provided solely for informational purposes;
(5) are not warranted to be complete, accurate or timely; and
(6) may be drawn from fund data published on various dates.

Morningstar and Phillip Securities Pte Ltd are not responsible for any trading decisions, damages or other losses related to the Information or its use. Please verify all of the Information before using it and don’t make any investment decision except upon the advice of a professional financial adviser. Past performance is no guarantee of future results. The value and income derived from investments may go down as well as up.

For the most up-to-date fund’s data and information, a copy of the fund factsheet, information or prospectus may be obtained from the respective ETF issuer.